Grant R. Wilkinson

What is he best known for?

The fields of study he is best known for:

• Internal medicine
• Gene
• Enzyme

Grant R. Wilkinson focuses on Pharmacology, Internal medicine, Pharmacokinetics, Pharmacogenetics and Polymorphism. His work on Drug metabolism, Oral administration and Drug as part of general Pharmacology study is frequently linked to Nelfinavir, therefore connecting diverse disciplines of science. He combines subjects such as Metabolite, CYP3A and Bioavailability with his study of Oral administration.

His Internal medicine study combines topics in areas such as Gastroenterology, Endocrinology and CYP3A5, Genotype. His Pharmacokinetics research is multidisciplinary, incorporating perspectives in Supine position and Blood pressure. His work deals with themes such as Mephenytoin and Hydroxylation, which intersect with Polymorphism.

His most cited work include:

• A physiological approach to hepatic drug clearance (1631 citations)
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. (987 citations)
• Drug metabolism and variability among patients in drug response (912 citations)

What are the main themes of his work throughout his whole career to date?

Grant R. Wilkinson mainly focuses on Pharmacology, Internal medicine, Pharmacokinetics, Endocrinology and Oral administration. His Pharmacology research includes themes of Mephenytoin, Debrisoquin and Metabolite. His Internal medicine research incorporates elements of Gastroenterology, Pharmacogenetics and In vivo.

In Pharmacokinetics, Grant R. Wilkinson works on issues like Anesthesia, which are connected to Indocyanine green. His Endocrinology research integrates issues from Polymorphism and Half-life. His Oral administration study also includes fields such as

• Bioavailability which is related to area like Dosing,
• Midazolam together with CYP3A and Erythromycin breath test.

He most often published in these fields:

• Pharmacology (54.22%)
• Internal medicine (41.78%)
• Pharmacokinetics (39.11%)

What were the highlights of his more recent work (between 2003-2018)?

• Pharmacogenetics (21.33%)
• Pharmacology (54.22%)
• Internal medicine (41.78%)

In recent papers he was focusing on the following fields of study:

Grant R. Wilkinson mostly deals with Pharmacogenetics, Pharmacology, Internal medicine, CYP2C9 and Tariquidar. His Pharmacogenetics research is multidisciplinary, incorporating elements of Pharmacogenomics, Reverse-transcriptase inhibitor and Single-nucleotide polymorphism. Grant R. Wilkinson works mostly in the field of Pharmacology, limiting it down to topics relating to Erythromycin breath test and, in certain cases, Oral administration, as a part of the same area of interest.

His work is dedicated to discovering how CYP2C9, Bioinformatics are connected with Polymorphism, Aryl Hydrocarbon Hydroxylases and Maintenance dose and other disciplines. He has researched Tariquidar in several fields, including Animal studies and In vivo. His Midazolam study integrates concerns from other disciplines, such as Hypnotic, CYP3A, Triazolam and Bioavailability.

Between 2003 and 2018, his most popular works were:

• Drug metabolism and variability among patients in drug response (912 citations)
• Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. (848 citations)
• Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. (549 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Gene
• Enzyme

His main research concerns Pharmacogenetics, Pharmacology, Internal medicine, Efavirenz and CYP3A5. His Pharmacogenetics study is related to the wider topic of Genetics. His biological study focuses on Maintenance dose.

His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Immunology and Reverse-transcriptase inhibitor. Grant R. Wilkinson has included themes like CYP2C19, Sida, Cytochrome P-450 CYP2B6 and Oncology in his CYP3A5 study. His research integrates issues of Pharmacokinetics and Immunopathology in his study of Cytochrome P-450 CYP2B6.